nova DISCOVERY

The future of clinical trials

Conquer the complexity of biology with clinical trial simulations

NOVA's mission is to support better clinical development of new drugs matching them with optimal responding patients. Using the JINKŌ® platform, clinical trials are simulated with a computational model of the disease of interest and virtual patients of any specific context or geography.

When compared with traditional clinical development, participants in the FDA's Model-Informed Drug Development Pilot Program note significant savings both in time - up to 2 years - as well as in cost -up to $70 million*.

US FDA selected NOVA for the MIDD Pilot Program in 2019 to present its approach to model design and validation.

FDA U.S. FOOD & DRUG ADMINISTRATION

Main advantages of *in silico* modeling

01 Accelerate clinical development timelines

02 Solve data & evidence gaps

03 Reduce sample size

04 Increase clinical trials probability of success

05 Address ethical concerns

JINKO® delivers solutions for each critical development painpoint



Tailoring our modeling offer to your needs

Mechanistic models of disease and virtual patients with JINKO® are aimed at helping drug developers generate new insights and manage the complexity of human biology.
Disease models are translated into mathematical representations of physiological knowledge.

Existing trial data can be harmonized and extrapolated. When no data from previous trials are available, trials can be simulated to generate data including fully-functional synthetic control arms with the option to use digital twins.



With more than 160 years of cumulative experience, NOVA has assembled the world's largest biomodeling team over the past 10 years.



Superiority of JINKO® over analytical approaches only based on data

Leverage curated knowledge and available data

01
Allow working in data-poor environments

02
Fill data gaps

03
Manage hidden variables

Collaborate in a white box environment

04
Full auditability & traceability

05
Easy-to-use for non-modelers

Useful resources

Publications

*Perspective on the Benefits Realized From the FDA's MIDD Pilote Programme
Verifying and Validating Quantitative Systems Pharmacology and In Silico Models in Drug Development
Scientific and regulatory evaluation of mechanistic in silico drug and disease models in drug development
Possible Contexts of Use for In Silico trials methodologies

Case studies

Lung Adenocarcinoma - non-small cell lung cancer
Myocardial reperfusion injury

Blog posts

Bulding trust in *in silico* modeling
Mechanistic models and AI
The power of synthetic control arms

They trust us

Takeda · Janssen · Servier · OM Pharma · erytech · ElsaLys Biotech · ENYO Pharma · Thera technologies · Shire

Novadiscovery
www.novadiscovery.com
contact@novadiscovery.com
+33 9 72 53 13 00

Europe
1 place Verrazzano,
69009, Lyon
France

USA
New York

MKT-0003 Rev.C